cerezyme

Multiple Suitors Could Be Looking to Buy Genzyme

Rumors are that Sanofi has proposed to buy Genzyme for $70 a share. But analysts believe the likes of Pfizer and the U.K. 's GlaxoSmithKline could be interested as well.

Genzyme's bad year gets worse: Experimental kidney drug a no-go

Big dosage, big profit: Does Genzyme encourage larger dosages than we need?